Randomized Phase II Trial of Pazopanib Versus Placebo in Patients With Advanced Extrapancreatic Neuroendocrine Tumors (Alliance A021202)
Pazopanib compared with placebo significantly improves PFS in patients with progressive epNET, confirming that the VEGF signaling pathway is a valid target for therapy in epNET. However, after integrating the associated risks relative to the benefits, further development of pazopanib in this clinical context is not planned.
Authors
- Spencer C. Behr (ORCID: https://orcid.org/0000-0001-9400-0543)
- Jeffrey A. Meyerhardt (ORCID: https://orcid.org/0000-0002-1120-0898)
- Emily K. Bergsland (ORCID: https://orcid.org/0000-0001-7754-6552)
- Michael L. Maitland (ORCID: https://orcid.org/0000-0002-2476-5732)
- Alan P. Venook (ORCID: https://orcid.org/0000-0001-9749-6548)
- Andrew B. Nixon (ORCID: https://orcid.org/0000-0003-3971-2964)
- Lawrence H. Schwartz
- Gina L. Mazza (ORCID: https://orcid.org/0000-0002-5305-6193)
- Jonathan Strosberg (ORCID: https://orcid.org/0000-0001-8405-218X)
- Donna Niedzwiecki (ORCID: https://orcid.org/0000-0002-3566-0450)
- Eileen Mary O'Reilly (ORCID: https://orcid.org/0000-0002-8076-9199)
- Priya Kumthekar (ORCID: https://orcid.org/0000-0001-5923-0677)
- J. Philip Kuebler
- Susan Geyer
- Timothy R. Asmis
Institutions
- Mayo Clinic (US)
- Memorial Sloan Kettering Cancer Center (US)
- Duke University (US)
- University of California, San Francisco (US)
- Ottawa Hospital (CA)
- Moffitt Cancer Center (US)
- Northwestern Memorial Hospital (US)
- Virginia Cancer Institute (US)
- Dana-Farber Cancer Institute (US)
- Duke Medical Center (US)
- Columbus Community Clinical Oncology Program (US)
Publication Details
- Journal
- Journal of Clinical Oncology
- Published
- 2025-09-03
- DOI
- https://doi.org/10.1200/jco-24-02644
- Citations
- 1
- Primary Topic
- Neuroendocrine Tumor Research Advances
- Type
- article
- Field-Weighted Citation Impact
- 1.35